We are pleased to announce that Damian Mikulski, MD, PhD, from the Department of Biostatistics and Translational Medicine at the Medical University of Lodz, presented the study findings at the 23rd International Myeloma Society Annual Meeting and Exposition in Glasgow in both the Oral Poster Discussion and the poster session:
“Second Primary Malignancies After Autologous Transplantation for Multiple Myeloma in the Modern Treatment Era: Incidence, Risk Factors, and Prognostic Impact Using a Competing-Risk Approach.”
Conducted in collaboration with the team at The University of Texas MD Anderson Cancer Center, the study included more than 2,400 patients with multiple myeloma who underwent autologous hematopoietic stem cell transplantation.Second primary malignancies were diagnosed in 10.1% of patients, with myelodysplastic syndrome being the most frequent individual diagnosis. New cases continued to occur more than 10 years after transplantation, with no clear decline in event rates during later follow-up. SPM diagnosis was associated with poorer survival, particularly following hematologic SPM, although myeloma progression remained the predominant cause of death.
Dr. Mikulski received the Young Investigator Award for this work. The ceremony was held at the Kelvingrove Art Gallery and Museum, where he received the award from María-Victoria Mateos, MD, PhD.The findings were also featured by Blood Cancers Today, which highlighted their implications for the long-term care of patients following autologous transplantation:
Congratulations on this recognition and the international interest in the study!